AbbVie (MEX:ABBV) Current Accrued Expense: MXN581,069 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ABBV AbbVie Inc MEX:ABBV
68 GF Score
Price MXN4,370.00
GF Value MXN3,754.05
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbbVie Current Accrued Expense?

AbbVie MEX:ABBV -1.60% 68 Current Accrued Expense is MXN581,069 Mil as of Jun. 2026. GuruFocus rates MEX:ABBV with a GF Score™ of 68/100 and a GF Value™ of MXN3,754.05 (Modestly Overvalued). The stock has 5 warning signs investors should review.

AbbVie's Current Accrued Expense for the quarter that ended in Jun. 2026 was MXN581,069 Mil.

AbbVie's quarterly Current Accrued Expense increased from Dec. 2025 (MXN504,934 Mil) to Mar. 2026 (MXN609,036 Mil) but then declined from Mar. 2026 (MXN609,036 Mil) to Jun. 2026 (MXN581,069 Mil).

AbbVie's annual Current Accrued Expense increased from Dec. 2023 (MXN410,420 Mil) to Dec. 2024 (MXN543,583 Mil) but then declined from Dec. 2024 (MXN543,583 Mil) to Dec. 2025 (MXN504,934 Mil).

AbbVie Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for AbbVie's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Current Accrued Expense Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 354,358.84 385,786.85 410,420.34 543,582.96 504,933.85

AbbVie Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 607,147.55 616,713.66 504,933.85 609,036.41 581,069.15
MEX:ABBV
68GF Score
AbbVie Inc MEX:ABBV
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of MXN581,069 Mil mean?
AbbVie (MEX:ABBV) has a Current Accrued Expense of MXN581,069 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on AbbVie and its competitors.
Is AbbVie's Current Accrued Expense too high?
AbbVie's current Current Accrued Expense is MXN581,069 Mil. Overall, AbbVie has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Current Accrued Expense compare to MRK and JNJ?
AbbVie's Current Accrued Expense of MXN581,069 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on AbbVie and its competitors. AbbVie's current Current Accrued Expense is MXN581,069 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (MEX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN3,754.05, compared to a current price of MXN4,370.00 — trading 16.4% above its estimated fair value. The current Current Accrued Expense is MXN581,069 Mil. AbbVie's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For AbbVie (MEX:ABBV), the current Current Accrued Expense is MXN581,069 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (MEX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of MXN4,370.00 is trading 16.4% above its estimated GF Value™ of MXN3,754.05. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for MEX:ABBV:

  • Current Accrued Expense: MXN581,069 Mil
  • GF Value™: MXN3,754.05 vs. price of MXN4,370.00 (16.4% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
68GF Score

Get the complete analysis for MEX:ABBV

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,370.00
Price
MXN3,754.05
GF Value